The technology used in Moderna's COVID-19 vaccine has been found to carry toxicity risks, according to scientists from the company. In a new paper published by Nature Reviews Drug Discovery, the scientists discussed the challenges of de-risking potential toxicities associated with mRNA technology, which is used in both the Moderna and Pfizer COVID-19 vaccines.
The mRNA technology involves delivering modified messenger ribonucleic acid (mRNA) using lipid nanoparticles (LNP). The scientists outlined several toxicity risks associated with this technology, including the structural components of the lipid nanoparticles, production methods, route of administration, and proteins produced from complexed mRNAs. They highlighted PEGlyated lipid nanoparticles as the most potentially reactogenic component, which may trigger hypersensitivity reactions and allergic responses.
The paper drew from prior publications and data, and the authors did not conduct any new experiments. However, they cited studies that found mRNA and spike protein from Moderna's vaccine in various parts of the human body weeks or even months after vaccination, contradicting initial claims that these materials would be eliminated within days.
Despite the identified risks, the scientists emphasized that Moderna's COVID-19 vaccine is safe and effective. They also highlighted the potential for rapid modifications with mRNA technology, suggesting that repeat administration may be necessary due to the transient nature of mRNA.
Reducing toxicity risks with mRNA-based vaccines and drugs is a complex task, according to the scientists. They suggested a multi-pronged approach that includes advanced testing in laboratories and adjustments to preclinical animal trials to better account for differences in human and animal physiology.
Moderna, along with other companies, is currently testing various new mRNA products, including influenza vaccines and cancer treatments. Moderna's CEO, Stephane Bancel, expressed excitement about their pipeline, with up to 15 launches expected in the next five years.
In response to the paper, Dr. Robert Malone, one of the inventors of mRNA technology, expressed concerns. He suggested that the article may be a limited hangout, a form of misdirection used as a propaganda technique. Dr. Malone questioned whether the risks associated with mRNA-based vaccines were adequately addressed in the paper.
In summary, the paper published by Moderna's scientists raises concerns about the toxicity risks associated with mRNA technology used in COVID-19 vaccines. Despite these risks, the scientists maintain that the vaccines are safe and effective. However, outside experts, such as Dr. Malone, have raised questions about the transparency of the information provided in the paper. As further research and investigations continue, it is essential to evaluate the potential risks and benefits of mRNA-based vaccines thoroughly.
